EMH
0.38
76.7%
C7A
0.002
-50%
DTM
0.055
66.7%
BOC
0.6
-47.8%
SRL
6.62
56.5%
TR2
0.395
-35.2%
CLE
0.065
54.8%
1TT
0.002
-33.3%
CBE
0.15
53.1%
BLZ
0.002
-33.3%
BIT
0.003
50%
LNU
0.002
-33.3%
EXR
0.063
50%
M2M
0.012
-29.4%
M2R
0.003
50%
MGU
0.005
-28.6%
TGN
0.225
50%
EZZ
1.7
-28.1%
MTM
1.02
48.9%
VMM
0.98
-26.9%
TNC
0.605
47.6%
PGY
0.003
-25%
AUR
0.023
43.8%
KOB
0.055
-23.6%
SRJ
0.017
41.7%
FMR
0.26
-21.2%
ZNC
0.115
40.2%
BOA
0.027
-20.6%
AEU
0.335
39.6%
AUG
0.035
-20.5%
EQR
0.064
39.1%
OEL
0.004
-20%
SKM
0.285
39%
VEN
0.004
-20%
DGR
0.025
38.9%
OCT
0.037
-19.6%
HIQ
0.025
38.9%
L1M
0.031
-18.4%
PTX
0.074
37%
DKM
0.14
-17.6%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759